ARS Pharmaceuticals (SPRY) Gains from Investment Securities (2022)
ARS Pharmaceuticals (SPRY) posted Gains from Investment Securities of $143000.0 for Q4 2022, up 7250.0% sequentially from -$2000.0 in Q2 2022.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) Gains from Investment Securities (2022) Analysis & Trends
ARS Pharmaceuticals has reported Gains from Investment Securities for 1 years, with the latest figure at $143000.0 in Q4 2022.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $143000.0 in Q4 2022, while the trailing twelve-month figure through Sep 2023 was $143000.0 (changed N/A YoY) and the FY2022 annual result came in at $140000.0, up 3600.0% from the prior year.
- Gains from Investment Securities rose to $143000.0 in Q4 2022 per SPRY's latest filing, from -$2000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $143000.0 in Q4 2022 and troughed at -$2000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.12 Mn | 417.27 Mn | 20.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 143,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -1,000.00 |